Gibson Dunn has advised Arrowhead Pharmaceuticals on the deal. Arrowhead Pharmaceuticals and Novartis have entered into a global license and collaboration agreement concerning ARO-SNCA, Arrowhead’s preclinical...
Arrowhead and Novartis Sign Global Licensing Agreement for Preclinical RNA Therapy
Sanofi Acquires Greater China Rights to Arrowhead’s RNAi Therapeutic Candidate from Visirna Therapeutics
Gibson Dunn has advised Arrowhead Pharmaceuticals on the deal. An asset purchase agreement has been executed under which Sanofi will acquire the rights to develop and...
Arrowhead Pharmaceuticals’ Lincense Collaboration Agreement with Sarepta Therapeutics
Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global...
Arrowhead Pharmaceuticals’ Financing Agreement with Sixth Street
Gibson, Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Rose advised Sixth Street. Arrowhead...
Arrowhead Pharmaceuticals’ $450 Million Common Stock Offering
Gibson, Dunn & Crutcher LLP is advising Arrowhead Pharmaceuticals, Inc. on the offering. Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the pricing of an underwritten registered offering...